Resource implications of expanding the use of donation after circulatory determination of death in liver transplantation

Liver Transplantation

Volumn 18, Issue 7, 2012, Pages 771-778

  Broomhead, Robert Hayden ^a   Patel, Sanjiv ^a   Fernando, Bimbi ^a   O'Beirne, James ^a   Mallett, Susan ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; FRESH FROZEN PLASMA; HEPARIN; HYPERTENSIVE FACTOR; LACTIC ACID;

ADULT; ARTICLE; ASSISTED VENTILATION; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BRAIN DEATH; CADAVER DONOR; CLINICAL ARTICLE; CONTROLLED STUDY; DONATION AFTER BRAIN DEATH; DONATION AFTER CIRCULATORY DETERMINATION OF DEATH; DRUG EFFECT; ERYTHROCYTE TRANSFUSION; FEMALE; FIBRINOLYSIS; GRAFT FAILURE; GRAFT SURVIVAL; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; HYPERFIBRINOLYSIS; INCIDENCE; INTENSIVE CARE; INTERMETHOD COMPARISON; LENGTH OF STAY; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; MODEL FOR END STAGE LIVER DISEASE SCORE; PERIOPERATIVE PERIOD; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; POSTREPERFUSION SYNDROME; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; SCORING SYSTEM; SURVIVAL TIME; THROMBOCYTE TRANSFUSION; VASCULAR DISEASE;

ADULT; BRAIN DEATH; COHORT STUDIES; FEMALE; GRAFT SURVIVAL; GREAT BRITAIN; HEPARIN; HUMANS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PREVALENCE; REPERFUSION; RESOURCE ALLOCATION; RETROSPECTIVE STUDIES; TISSUE AND ORGAN PROCUREMENT; TISSUE DONORS; WAITING LISTS;

EID: 84863956158     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23406     Document Type: Article

References (41)

1. National Health Service Blood and Transplant. Annual review 2010/11. Accessed February 2012.
2. Abt PL, Desai NM, Crawford MD, Forman LM, Markmann JW, Olthoff KM, Markmann JF,. Survival following liver transplantation from non-heart-beating donors. Ann Surg 2004; 239: 87-92.
3. Merion RM, Pelletier SJ, Goodrich N, Englesbe MJ, Delmonico FL,. Donation after cardiac death as a strategy to increase deceased donor liver availability. Ann Surg 2006; 244: 555-562.
4. D'alessandro AM, Hoffmann RM, Knechtle SJ, Odorico JS, Becker YT, Musat A, et al. Liver transplantation from controlled non-heart-beating donors. Surgery 2000; 128: 579-588.
5. Summers DM, Counter C, Johnson RJ, Murphy PG, Neuberger JM, Bradley JA,. Is the increase in DCD organ donors in the United Kingdom contributing to a decline in DBD donors? Transplantation 2010; 90: 1506-1510.
6. Casavilla A, Ramirez C, Shapiro R, Nghiem D, Miracle K, Bronsther O, et al. Experience with liver and kidney allografts from non-heart-beating donors. Transplantation 1995; 59: 197-203.
7. Muiesan P, Girlanda R, Jassem W, Melendez HV, O'Grady J, Bowles M, et al. Single-center experience with liver transplantation from controlled non-heartbeating donors: a viable source of grafts. Ann Surg 2005; 242: 732-738.
8. Paugam-Burtz C, Kavafyan J, Merckx P, Dahmani S, Sommacale D, Ramsay M, et al. Postreperfusion syndrome during liver transplantation for cirrhosis: outcome and predictors. Liver Transpl 2009; 15: 522-529.
9. Hilmi I, Horton CN, Planinsic RM, Sakai T, Nicolau-Raducu R, Damian D, et al. The impact of postreperfusion syndrome on short-term patient and liver allograft outcome in patients undergoing orthotopic liver transplantation. Liver Transpl 2008; 14: 504-508.
10. Bellamy MC, Galley HF, Webster NR,. Changes in inflammatory mediators during orthotopic liver transplantation. Br J Anaesth 1997; 79: 338-341.
11. Graf J, Mühlhoff C, Doig GS, Reinartz S, Bode K, Dujardin R, et al. Health care costs, long-term survival, and quality of life following intensive care unit admission after cardiac arrest. Crit Care 2008; 12: R92.
12. Bennett D, Bion J,. ABC of intensive care: organisation of intensive care. BMJ 1999; 318: 1468-1470.
13. Hansard (House of Commons Daily Debates). Written answers for June 15, 2005. Accessed February 2012.
14. Grewal HP, Willingham DL, Nguyen J, Hewitt WR, Taner BC, Cornell D, et al. Liver transplantation using controlled donation after cardiac death donors: an analysis of a large single-center experience. Liver Transpl 2009; 15: 1028-1035.
15. Selck FW, Grossman EB, Ratner LE, Renz JF,. Utilization, outcomes, and retransplantation of liver allografts from donation after cardiac death: implications for further expansion of the deceased-donor pool. Ann Surg 2008; 248: 599-607.
16. Taner CB, Bulatao IG, Willingham DL, Perry DK, Sibulesky L, Pungpapong S, et al. Events in procurement as risk factors for ischemic cholangiopathy in liver transplantation using donation after cardiac death donors. Liver Transpl 2012; 18: 100-111.
17. Pine JK, Aldouri A, Young AL, Davies MH, Attia M, Toogood GJ, et al. Liver transplantation following donation after cardiac death: an analysis using matched pairs. Liver Transpl 2009; 15: 1072-1082.
18. Salvalaggio PR, Dzebisashvili N, MacLeod KE, Lentine KL, Gheorghian A, Schnitzler MA, et al. The interaction among donor characteristics, severity of liver disease, and the cost of liver transplantation. Liver Transpl 2011; 17: 233-242.
19. Jay CL, Lyuksemburg V, Kang R, Preczewski L, Stroupe K, Holl JL, et al. The increased costs of donation after cardiac death liver transplantation: caveat emptor. Ann Surg 2010; 251: 743-748.
20. Shaked A, Nunes FA, Olthoff KM, Lucey MR,. Assessment of liver function: pre- and peritransplant evaluation. Clin Chem 1997; 43 (pt 2): 1539-1545.
21. Katz E, Mor E, Schwartz ME, Theise N, Patel T, Miller CM,. Preservation injury in clinical liver transplantation: incidence and effect on rejection and survival. Clin Transplant 1994; 8: 492-496.
22. Glanemann M, Langrehr JM, Stange BJ, Neumann U, Settmacher U, Steinmüller T, Neuhaus P,. Clinical implications of hepatic preservation injury after adult liver transplantation. Am J Transplant 2003; 3: 1003-1009.
23. Wang MF, Jin ZK, Chen DZ, Li XL, Zhao X, Fan H,. Risk factors of severe ischemic biliary complications after liver transplantation. Hepatobiliary Pancreat Dis Int 2011; 10: 374-379.
24. Mathur AK, Heimbach J, Steffick DE, Sonnenday CJ, Goodrich NP, Merion RM,. Donation after cardiac death liver transplantation: predictors of outcome. Am J Transplant 2010; 10: 2512-2519.
25. Richer M, Robert S, Lebel M,. Renal hemodynamics during norepinephrine and low-dose dopamine infusions in man. Crit Care Med 1996; 24: 1150-1156.
26. Bellomo R, Kellum JA, Wisniewski SR, Pinsky MR,. Effects of norepinephrine on the renal vasculature in normal and endotoxemic dogs. Am J Respir Crit Care Med 1999; 159 (pt 1): 1186-1192.
27. Krejci V, Hiltebrand LB, Sigurdsson GH,. Effects of epinephrine, norepinephrine, and phenylephrine on microcirculatory blood flow in the gastrointestinal tract in sepsis. Crit Care Med 2006; 34: 1456-1463.
28. Broomhead RH, Mallett SV,. Clinical aspects of coagulation. Anaesth Intensive Care Med 2010; 11: 195-199.
29. Blonski W, Siropaides T, Reddy KR,. Coagulopathy in liver disease. Curr Treat Options Gastroenterol 2007; 10: 464-473.
30. Dzik WH, Arkin CF, Jenkins RL, Stump DC,. Fibrinolysis during liver transplantation in humans: role of tissue-type plasminogen activator. Blood 1988; 71: 1090-1095.
31. Legnani C, Palareti G, Rodorigo G, Gozzetti G, Mazziotti A, Martinelli G, et al. Protease activities, as well as plasminogen activators, contribute to the "lytic" state during orthotopic liver transplantation. Transplantation 1993; 56: 568-572.
32. McNicol PL, Liu G, Harley ID, McCall PR, Przybylowski GM, Bowkett J, et al. Patterns of coagulopathy during liver transplantation: experience with the first 75 cases using thrombelastography. Anaesth Intensive Care 1994; 22: 659-665.
33. Harding SA, Mallett SV, Peachey TD, Cox DJ,. Use of heparinase modified thrombelastography in liver transplantation. Br J Anaesth 1997; 78: 175-179.
34. Quartin AA, Kett DH, Schein RMH,. Relationship of duration of ventilatory support with late mortality in medical intensive care patients. Crit Care Med 1994; 22: A43.
35. Gracey DR, Naessens JM, Krishan I, Marsh HM,. Hospital and posthospital survival in patients mechanically ventilated for more than 29 days. Chest 1992; 101: 211-214.
36. Kollef MH,. The prevention of ventilator-associated pneumonia. N Engl J Med 1999; 340: 627-634.
37. Foxton MR, Al-Freah MA, Portal AJ, Sizer E, Bernal W, Auzinger G, et al. Increased Model for End-Stage Liver Disease score at the time of liver transplant results in prolonged hospitalization and overall intensive care unit costs. Liver Transpl 2010; 16: 668-677.
38. 2007 OPTN/SRTR annual report. Accessed February 2012.
39. Ho KJ, Owens CD, Johnson SR, Khwaja K, Curry MP, Pavlakis M, et al. Donor postextubation hypotension and age correlate with outcome after donation after cardiac death transplantation. Transplantation 2008; 85: 1588-1594.
40. Skaro AI, Wang E, Lyuksemburg V, Abecassis M,. Donation after cardiac death liver transplantation: time for policy to catch up with practice. Liver Transpl 2012; 18: 5-8.
41. Dubbeld J, Hoekstra H, Farid W, Ringers J, Porte RJ, Metselaar HJ, et al. Similar liver transplantation survival with selected cardiac death donors and brain death donors. Br J Surg 2010; 97: 744-753.